Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 17/20 | 0.53 |
| ▸ | PPARG | P37231 | 7/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927034 | 0.94 | EPHX2 (0.55) | EPHX2PPARGROCK2ROCK1 | |
| SCHEMBL13218656 | 0.85 | ROCK2 (0.53) | EPHX2PPARGROCK2KDM4EMAPT | |
| SCHEMBL6981710 | 0.81 | KDM4E (0.60) | ROCK2KDM4EMAPTROCK1 | |
| SCHEMBL3470919 | 0.80 | EPHX2 (0.54) | EPHX2PPARGROCK2ROCK1 | |
| SCHEMBL3470247 | 0.79 | EPHX2 (0.58) | EPHX2PPARGROCK2ROCK1 | |
| SCHEMBL3029239 | 0.78 | ROCK2 (0.54) | EPHX2PPARGROCK2MAPTROCK1 | |
| SCHEMBL27370813 | 0.77 | KDM4E (0.54) | ROCK2KDM4EMAPT | |
| SCHEMBL3026165 | 0.76 | EPHX2 (0.54) | EPHX2ROCK2KDM4EMAPTROCK1 | |
| SCHEMBL1787178 | 0.74 | EPHX2 (0.52) | EPHX2PPARGROCK2 | |
| SCHEMBL1791513 | 0.73 | EPHX2 (0.53) | EPHX2PPARGROCK2KDM4EROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GLAXOSMITHKLINE LLC | 2010-08-19 | — | — | US | disclosed |
| EP-2217068-A1 | NOVEL sEH INHIBITORS AND THEIR USE | GlaxoSmithKline LLC (US) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009049154-A1 | NOVEL sEH INHIBITORS AND THEIR USE | SMITHKLINE BEECHAM CORPORATION (US) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210655-A1 | NOVEL sEH INHIBITORS AND THEIR USE | EPHX1, NCEH1, FAH | EPHX2 5/4885PPARG 4031/4885ROCK2 396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.